Matt’s career has included development stages from early R&D to commercial deployment in a variety of sectors, including industrial and pharmaceutical biotechnology. In the biopharmaceutical sector, Matt was previously VP of Scientific Quality at CBR International Corp., a globally recognized pharmaceutical development consulting firm. Of note, one of the projects for a CBR client resulted in the first FDA-approved autologous cell therapy. Matt was also a founding employee of OPXBIO where he provided technical and strategic leadership for their development programs. His efforts contributed to the successful piloting and initial demonstration of a technology to produce 3-hydroxypropionic acid (a precursor to the commodity chemical, acrylic acid) from sugars via fermentation utilizing engineered microbes. In another program at OPXBIO, Matt successfully led a DOE ARPA-E sponsored effort to develop an engineered microbe capable of utilizing CO2 as a feedstock in the production of specialty fatty acids. Dr. Lipscomb received his B.S in Chemical Engineering from Clemson University and his Ph.D. in Chemical Engineering from the University of Colorado, Boulder.